in-cosmetics North America, the interactive personal care ingredient event in North America, will launch a brand-new programme for marketing and product development professionals when it returns to New York City in October 2017.
CordenPharma is pleased to announce that CordenPharma Latina, located near Sermoneta, Italy, has received news that the US-FDA warning letter previously received has been closed, with a closeout date of August 15, 2017. This success is the result of a holistic and systematic approach to remediate the observations throughout the facility. Since inception, CordenPharma’s Corporate Compliance Team has developed a company-wide strategic approach to enhancing all quality and compliance systems by systematically reviewing and assessing each CordenPharma facility and establishing harmonization programs, knowledge management and sharing of best practices. In order to ensure effectiveness, CordenPharma has planned a long-term high investment program in regards to corporate and quality systems, organizational structure and infrastructure, including a process to involve customers in improving transparency. CordenPharma’s Leadership Team is committed to enabling all facilities to operate according to the highest level of quality, compliance structures and systems, with a consistent focus on patient safety, guidelines, legislations, and strict adherence to current industry standards. CordenPharma is currently achieving and sustaining these quality and compliance objectives proactively through continuous improvement strategies and collaboration with regulatory agencies, with the aim to serve patients and customers worldwide as a reliable and benchmark CDMO partner in the pharmaceutical, biotech and healthcare industry.
A new dimethyl ether (DME) production plant, scheduled to open in the first half of 2018, is being built to supply Russian and Customs Union countries with high purity DME for cosmetic and technical products. Aerosolex has received authorization by the Dzerzhinsk municipal administration (Nizhny Novgorod, Russia) for the construction of a high-purity dimethyl ether (DME) production plant with the capacity of 10,000 tons per year. The authorization, which was obtained in August, follows a positive review in June 2017 of the design documentation and the results of engineering surveys.1
One of the UK’s top manufacturing exporters has criticised the Government for making the full transition to Brexit unnecessarily complex. The chemical and pharmaceutical industry, whose wider activities (manufacturing plus distribution) is the largest exporter of manufactured goods with annual exports of close to £50 billion, has questioned the value of an interim customs union.
Azelis has reinforced ties with Tagra Biotechnologies and its position in Asia Pacific with an exclusive distribution agreement in China. Azelis has been appointed as exclusive distributor by Tagra Biotechnologies to offer their range of RND microencapsulated actives and pigments in China for all Personal Care applications. This new partnership builds on agreements between the two companies in Europe, Canada, Australia and New Zealand, and will reinforce Azelis’s position in Asia Pacific as a leading distributor of speciality chemicals.
Olon a leading CDMO and generics supplier headquartered in Italy, has acquired Ricerca Biosciences’ Chemical Division in Ohio, USA. The acquisition strengthens Olon’s service offering in North America, and benefits Ricerca Biosciences by providing large scale manufacturing capabilities in Europe. Olon has acquired Ricerca Biosciences’ Chemical Division based in Concord, Ohio, USA. Ricerca Biosciences is a US‐based CRO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution. Ricerca’s extensive process/synthetic chemistry, analytical chemistry and engineering expertise provides a synergy that excels at first‐time scale‐ups and subsequent development of safe, reliable, robust and cost-effective manufacturing processes.
A new Chemical Service Company has been formed – WeylChem InnoTec is the “Technology and Innovation backbone of WeylChem Group of Companies”.
CordenPharma is investing €10 million in a new manufacturing line for veterinary drug products in CordenPharma Plankstadt, near Heidelberg in Germany. CordenPharma Plankstadt are experts in the development and manufacturing of solid dosage forms, specializing in the safe handling of highly potent APIs and drug products, with a full range of services from pharmaceutical development for phase I to III to commercial-scale manufacturing, packaging and pharma-logistics (CEE-hub).
CPhI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters. CPhI Worldwide looks back at previous Annual Reports to see how accurate their predictions were. CPhI Worldwide has announced the 2017 expert panel for the highly anticipated CPhI Worldwide Annual Industry Report (5th edition) – to be released in two parts; part one in late summer and part two during CPhI Worldwide (October 24-26, 2017 in Frankfurt). The report is a comprehensive and critically important publication that analyses key trends and innovations forecast by a panel of world class experts.
EUROTOX welcomes you to Bratislava for the 53rd Annual Congress, featuring over 30 symposia and workshops, and offering the chance to strengthen professional relationships through networking activities.